Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting, 20888-20889 [2014-08198]

Agencies

• Food and Drug Administration
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 79, Number 71 (Monday, April 14, 2014)]
[Notices]
[Pages 20888-20889]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-08198]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0001]


Circulatory System Devices Panel of the Medical Devices Advisory 
Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Circulatory System Devices Panel of the Medical 
Devices Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the Agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on May 6 and 7, 2014, from 
8 a.m. to 6 p.m.
    Location: Hilton Washington DC North/Gaithersburg, Salons A, B, C, 
and D, 620 Perry Pkwy., Gaithersburg, MD 20877. The hotel's telephone 
number is 301-977-8900.
    Contact Person: Jamie Waterhouse, Center for Devices and 
Radiological Health, Food and Drug Administration, 10903 New Hampshire 
Ave., Silver Spring, MD 20993, 301-796-3063, email: 
Jamie.Waterhouse@fda.hhs.gov, or FDA Advisory Committee Information 
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A 
notice in the Federal Register about last-minute modifications that 
impact a previously announced advisory committee meeting cannot always 
be published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate 
advisory committee meeting link, or call the advisory committee 
information line to learn about possible modifications before coming to 
the meeting.
    Agenda: On May 6, 2014, the committee will discuss, make 
recommendations, and vote on information related to the premarket 
approval application for the RESQCPR System sponsored by Advanced 
Circulatory Systems, Inc. The RESQCPR System is comprised of two 
devices: the RESQPOD 16.0 Impedance Threshold Device, and the RESQPUMP 
Active Compression Decompression CPR Device. These devices are used 
together during manual cardiopulmonary resuscitation (CPR) in an 
attempt to enhance venous return to the heart and blood flow to vital 
organs during CPR to ultimately increase survival and neurologic 
outcome in patients suffering from out of hospital cardiac arrest.
    Advanced Circulatory Systems, Inc. has proposed the following 
indications for use: the RESQCPR System is intended for use in the 
performance of CPR to increase survival with favorable neurologic 
function in adult patients with non-traumatic cardiac arrest.
    On May 7, 2014, during session I, the committee will discuss and 
make recommendations regarding the classification of membrane lung for 
long-term pulmonary support systems, one of the remaining preamendment 
Class III devices regulated under the 510(k) pathway. A membrane lung 
for long-term pulmonary support refers to the oxygenator component of 
an extracorporeal circuit used during long-term procedures, commonly 
referred to as extracorporeal membrane oxygenation (ECMO). An ECMO 
procedure provides assisted extracorporeal circulation and physiologic 
gas exchange of a patient's blood when an acute (reversible) condition 
prevents the patient's own body from providing the physiologic gas 
exchange needed to sustain life. The circuit is comprised of multiple 
device types, including, but not limited to, an oxygenator, blood pump, 
cannulae, heat exchanger, tubing, filters, monitors/detectors, and 
other accessories; the circuit components and configuration (e.g., 
arteriovenous, veno-venous) may differ based on the needs of the 
individual patient or the condition being treated. ECMO is currently 
used for patients with acute reversible respiratory or cardiac failure, 
unresponsive to optimal ventilation and/or pharmacologic management.
    On January 8, 2013 the FDA issued a proposed order which, if made 
final, would make the class III ECMO devices class II subject to 
premarket notification (510(k)) and special controls. FDA discussed the 
regulatory history of ECMO devices as part of the proposed order. On 
September 12, 2013, the classification of ECMO was discussed at a 
meeting of the Circulatory System Devices Panel. The Panel agreed with 
FDA's proposal to reclassify ECMO to class II (special controls) as 
outlined in the January 8, 2013, proposed order, but recommended that a 
panel be reconvened to discuss use of ECMO in an adult patient 
population as the September 12, 2013, panel meeting was focused on the 
use of ECMO in a pediatric patient population.
    The discussion at this panel meeting will involve making 
recommendations regarding regulatory classification to either reconfirm 
to class III (subject to premarket approval application (PMA)) or 
reclassify to class II and comment on whether special controls are 
adequate to assure the safety and effectiveness of this device in an 
adult patient population.
    On May 7, 2014, during session II, the committee will discuss and 
make recommendations regarding the classification of More-than-
Minimally Manipulated Allograft Heart Valves (MMM Allograft HVs). An 
MMM Allograft HV is a human valve or valved-conduit that has been 
aseptically recovered from qualified donors, dissected free from the 
human heart, and then subjected to a manufacturing process(es) which 
alters the original relevant characteristics of the tissue (cf. 21 CFR 
1271.3(f), 21 CFR 1271.10(a)(1), and 21 CFR 1271.20). The valve is then 
stored until needed by a recipient. An

[[Page 20889]]

example of such a manufacturing process is one which intentionally 
removes the cells and cellular debris, with the goal of reducing in 
vivo antigenicity.
    MMM Allograft HVs are considered preamendment devices because they 
were found substantially equivalent to devices in commercial 
distribution prior to May 28, 1976, when the Medical Device Amendments 
became effective. MMM Allograft HVs are currently regulated under the 
heading of ``Heart Valve, More than Minimally Manipulated Allograft'', 
Product Code OHA, as unclassified devices and reviewed under the 
premarket notification, 510(k), authority. FDA is seeking committee 
input on the safety and effectiveness of MMM Allograft HVs and the 
regulatory classification for MMM Allograft HVs.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting 
link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
April 28, 2014. On May 6, oral presentations from the public will be 
scheduled between approximately 1 p.m. and 2 p.m. On May 7, oral 
presentations from the public will be scheduled between approximately 
9:30 a.m. and 10 a.m. for session I and between 2 p.m. and 2:30 p.m. 
for session II. Those individuals interested in making formal oral 
presentations should notify the contact person and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their presentation 
on or before April 18, 2014. Time allotted for each presentation may be 
limited. If the number of registrants requesting to speak is greater 
than can be reasonably accommodated during the scheduled open public 
hearing session, FDA may conduct a lottery to determine the speakers 
for the scheduled open public hearing session. The contact person will 
notify interested persons regarding their request to speak by April 21, 
2014.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact James Clark, 
Conference Management Staff, at James.Clark@fda.hhs.gov or 301-796-5293 
at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: April 4, 2014.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2014-08198 Filed 4-11-14; 8:45 am]
BILLING CODE 4160-01-P